Overview

A Study of Olanzapine in Patients With Schizophrenia

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study is to confirm if the efficacy of intramuscular injection (IM) olanzapine 10 milligrams (mg) in patients with an exacerbation of schizophrenia with acute psychotic agitation is greater than intramuscular placebo by comparing changes from baseline to 2 hours after the first IM injection of agitation.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine